Navigation Links
Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
Date:9/10/2013

ted with ICS, as recommended in the guidelines, continue to experience symptoms that can impact their ability to lead a full life."

Despite current treatment options, at least 40 percent of patients with asthma remain symptomatic and may experience potentially life-threatening asthma exacerbations (attacks).

"We are committed to studying tiotropium across a wide range of asthma patients from mild to severe across all age groups, and we are encouraged by the results we have seen with tiotropium in asthma to date," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Results from the MezzoTinA-asthma® studies presented at ERS build on previous positive study results for tiotropium from the PrimoTinA-asthma® studies in patients with severe asthma. Collectively, these results show tiotropium, when approved, could become an important new option for asthma patients across a range of severities who remain symptomatic despite current standard treatments."

Key Results from the MezzoTinA-Asthma® Phase 3 Studies
The data are from a set of replicate Phase 3 studies; MezzoTinA-asthma® 1 and MezzoTinA-asthma® 2 are two paired international, double-blind, randomized, placebo- and active-controlled, parallel-group trials that involved asthma patients ages 18-75 years who remained symptomatic while on medium-dose ICS. A total of 2,103 patients were randomized to receive tiotropium 2.5 mcg or 5 mcg once daily delivered via the Respimat® inhaler, salmeterol 50 mcg twice daily (as the active comparator), or placebo, for 24 weeks. Pre-specified co-primary endpoints were peak forced expiratory volume (FEV1)(0-3h) response and trough FEV1 response after 24 weeks. ACQ responder rate was the third co-primary endpoint, performed on
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
4. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
5. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
6. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
7. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
8. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
9. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
10. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
11. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 ResMed (NYSE: RMD ) ... against Chinese medical device manufacturer BMC Medical Co., Ltd. ... BMC,s masks listed below infringe ResMed,s patents, and entered an ... in the United States : ... , Willow nasal pillows mask , iVolve full ...
(Date:12/24/2014)... , Dec. 23, 2014  The American ... blood pressure target for people with diabetes and ... or high doses of statins, in keeping with ... enacted by the American College of Cardiology (ACC) ... reflected in the most recent changes to the ...
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 7, 2010 Where do you start when trying to ... ), an independent nonprofit that researches the best approaches to ... release of its 5th annual list of Top 10 ... free download with registration, the list features the ...
... Research Group (MRG), the global authority on medical technology ... the US clot management device market.   ... report provides important insight into the device-based treatments ... of medical device manufacturers in this field. The report ...
Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... from the University of Georgia and the Mayo Clinic in ... a mouse model that mimics 90 percent of human breast ... treatments. The vaccine, described this week in ... National Academy of Sciences , reveals a promising new strategy ...
... Researchers from the University of Maryland School of Medicine and ... exercise and computerized memory training to see if those activities ... type of memory that will be examined is known as ... use it in a new way. Many Parkinson,s ...
... cancer cells, scientists at Johns Hopkins have found that a ... ability of pre-leukemic cells to repair broken bits of their ... their experiments, expected to be presented at the 53rd Annual ... Dec. 12, have already prompted clinical trials of the drugs ...
... finds that patients who are moved into isolation during a ... a potentially dangerous change in mental status that often affects ... not at increased risk. The study, published in the ... the journal of the Society for Healthcare Epidemiology of America, ...
... have discovered a new way to target cancer through manipulating ... The findings, published today [12 Dec] in the journal ... producing their own blood vessels. Cancer cells gain ... vessels grow, helping deliver oxygen and sugars to the tumour. ...
... MONDAY, Dec. 12 (HealthDay News) -- An advisory panel to the ... Evra birth control patch carries a higher risk of blood clots ... off drug store shelves. The panel, which based its decision ... 19 to 5 that the benefits of Johnson & Johnson,s Ortho ...
Cached Medicine News:Health News:Scientists develop vaccine that attacks breast cancer in mice 2Health News:Scientists develop vaccine that attacks breast cancer in mice 3Health News:Scientists develop vaccine that attacks breast cancer in mice 4Health News:Exercise/memory research for Parkinson's 2Health News:Exercise/memory research for Parkinson's 3Health News:'PARP' drug sabotages DNA repair in pre-leukemic cells 2Health News:'PARP' drug sabotages DNA repair in pre-leukemic cells 3Health News:Patient isolation associated with hospital delirium: study 2Health News:Scientists discover new way to target cancer 2Health News:FDA Panel Cites Clot Risk From Contraceptive Patch 2
... purpose incubators designed to provide ... uniformity required for the most ... microprocessor controlled incubators feature push-button ... digital display, and built-in over-temperature ...
... available in five different models. Choose mechanical ... Ft. (39 liters), 2.5 cu. Ft. (71.5 ... Equally important, Precision Economy Incubators combine a ... stability, and uniformity. As a result, you ...
Aspheric diagnostic lens. 90D...
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Medicine Products: